The nature of antioxidant defense mechanisms: a lesson from transgenic studies. [1998](IR91)
// - - Begin memo item - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - //
(Memo Item created on December 17, 2011 01:41 PM)
- - - Begin title or keyword:
The nature of antioxidant defense mechanisms: a lesson from transgenic studies.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533365/
- - - End title or keyword:
Environ Health Perspect. 1998 October; 106(Suppl 5): 1219–1228.
PMCID: PMC1533365
Copyright notice
Research Article
The nature of antioxidant defense mechanisms: a lesson from transgenic studies.
Y S Ho, J L Magnenat, M Gargano, and J Cao
Institute of Chemical Toxicology, Wayne State University, Detroit, MI 48201, USA. yho@wayne.edu
Abstract
Reactive oxygen species (ROS) have been implicated in the pathogenesis of many clinical disorders such as adult respiratory distress syndrome, ischemia-reperfusion injury, atherosclerosis, neurodegenerative diseases, and cancer. Genetically engineered animal models have been used as a tool for understanding the function of various antioxidant enzymes in cellular defense mechanisms against various types of oxidant tissue injury. Transgenic mice overexpressing three isoforms of superoxide dismutase, catalase, and the cellular glutathione peroxidase (GSHPx-1) in various tissues show an increased tolerance to ischemia-reperfusion heart and brain injury, hyperoxia, cold-induced brain edema, adriamycin, and paraquat toxicity. These results have provided for the first time direct evidence demonstrating the importance of each of these antioxidant enzymes in protecting the animals against the injury resulting from these insults, as well as the effect of an enhanced level of antioxidant in ameliorating the oxidant tissue injury. To evaluate further the nature of these enzymes in antioxidant defense, gene knockout mice deficient in copper-zinc superoxide dismutase (CuZnSOD) and GSHPx-1 have also been generated in our laboratory. These mice developed normally and showed no marked pathologic changes under normal physiologic conditions. In addition, a deficiency in these genes had no effects on animal survival under hyperoxida. However, these knockout mice exhibited a pronounced susceptibility to paraquat toxicity and myocardial ischemia-reperfusion injury. Furthermore, female mice lacking CuZnSOD also displayed a marked increase in postimplantation embryonic lethality. These animals should provide a useful model for uncovering the identity of ROS that participate in the pathogenesis of various clinical disorders and for defining the role of each antioxidant enzyme in cellular defense against oxidant-mediated tissue injury.
// - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - End memo item - - //
// - - Begin memo item - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - //
(Memo Item created on December 17, 2011 01:47 PM)
- - - Begin title or keyword:
English to Chinese translation of some medical terms relevant to this paper
- - - End title or keyword:
ischemia-reperfusion injury
ischemia
【醫學】局部缺血
reperfusion
再灌注
// - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - End memo item - - //
2011年12月16日 星期五
The nature of antioxidant defense mechanisms: a lesson from transgenic studies. [1998](IR91)
2011年11月18日 星期五
The central role of glutathione in the pathophysiology of human diseases [2007](IR91)
The central role of glutathione in the pathophysiology of human diseases.[2007](IR91)
The central role of glutathione in the pathophysiology of human diseases.[2007](IR91)
// - - Begin memo item - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - //
(Memo Item created on November 19, 2011 01:48 PM)
- - - Begin title or keyword:
The central role of glutathione in the pathophysiology of human diseases.
http://www.ncbi.nlm.nih.gov/pubmed/18158646
- - - End title or keyword:
Arch Physiol Biochem. 2007 Oct-Dec;113(4-5):234-58.
The central role of glutathione in the pathophysiology of human diseases.
Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI.
Source
Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.
Abstract
Reduced glutathione (L-gamma-glutamyl-L-cysteinyl-glycine, GSH) is the prevalent low-molecular-weight thiol in mammalian cells. It is formed in a two-step enzymatic process including, first, the formation of gamma-glutamylcysteine from glutamate and cysteine, by the activity of the gamma-glutamylcysteine synthetase; and second, the formation of GSH by the activity of GSH synthetase which uses gamma-glutamylcysteine and glycine as substrates. While its synthesis and metabolism occur intracellularly, its catabolism occurs extracellularly by a series of enzymatic and plasma membrane transport steps. Glutathione metabolism and transport participates in many cellular reactions including: antioxidant defense of the cell, drug detoxification and cell signaling (involved in the regulation of gene expression, apoptosis and cell proliferation). Alterations in its concentration have also been demonstrated to be a common feature of many pathological conditions including diabetes, cancer, AIDS, neurodegenerative and liver diseases. Additionally, GSH catabolism has been recently reported to modulate redox-sensitive components of signal transduction cascades. In this manuscript, we review the current state of knowledge on the role of GSH in the pathogenesis of human diseases with the aim to underscore its relevance in translational research for future therapeutic treatment design.
PMID: 18158646 [PubMed - indexed for MEDLINE]
// - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - End memo item - - //
2011年9月23日 星期五
Glutathione dysregulation and the etiology and progression of human diseases {Major pathways of glutathione homeostasis in mammalian cells}[2009](IR92)
GSTs act by conjugating the thiol group from glutathione (GSH; g-glutamyl-cysteinyl-glycine) to compounds that possess an electrophilic center [2007]
Acetaminophen Poisoning - an Evidence-Based Consensus Guideline for Out-of-Hospital Management; Clinical Toxicology [2006](IR91)
2011年6月10日 星期五
Regulation of neuronal glutathione synthesis. [2008](IR91)
Regulation of neuronal glutathione synthesis.
http://www.ncbi.nlm.nih.gov/pubmed/19008644
J Pharmacol Sci. 2008 Nov;108(3):227-38. Epub 2008 Nov 13.
Regulation of neuronal glutathione synthesis.
Aoyama K, Watabe M, Nakaki T.
Department of Pharmacology, Teikyo University School of Medicine, Itabashi, Tokyo, Japan.
Abstract
The brain is among the major organs generating large amounts of reactive oxygen species and is especially susceptible to oxidative stress. Glutathione (GSH) plays critical roles as an antioxidant, enzyme cofactor, cysteine storage form, the major redox buffer, and a neuromodulator in the central nervous system. GSH deficiency has been implicated in neurodegenerative diseases. GSH is a tripeptide comprised of glutamate, cysteine, and glycine. Cysteine is the rate-limiting substrate for GSH synthesis within neurons. Most neuronal cysteine uptake is mediated by sodium-dependent excitatory amino acid transporter (EAAT) systems, known as excitatory amino acid carrier 1 (EAAC1). Previous studies demonstrated EAAT is vulnerable to oxidative stress, leading to impaired function. A recent study found EAAC1-deficient mice to have decreased brain GSH levels and increased susceptibility to oxidative stress. The function of EAAC1 is also regulated by glutamate transporter associated protein 3-18. This review focuses on the mechanisms underlying GSH synthesis, especially those related to neuronal cysteine transport via EAAC1, as well as on the importance of GSH functions against oxidative stress.
PMID: 19008644 [PubMed - indexed for MEDLINE] Free full text
2011年3月4日 星期五
Molecular inflammation - Underpinnings of aging and age-related diseases [2009](IR91)
Molecular inflammation: Underpinnings of aging and age-related diseases [2009](IR91)
// - - Begin memo item - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - //
(Memo Item created on March 4, 2011 04:33 PM)
- - - Begin title or keyword:
Molecular inflammation: underpinnings of aging and age-related diseases.
http://www.ncbi.nlm.nih.gov/pubmed/18692159
- - - End title or keyword:
Ageing Res Rev. 2009 Jan;8(1):18-30. Epub 2008 Jul 18.
Molecular inflammation: underpinnings of aging and age-related diseases.
Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C.
Department of Pharmacy, Longevity Science and Technology Institutes, Research Institute for Drug Development, Pusan National University, Geumjeong-gu, Busan 609-735, South Korea. hyjung@pusan.ac.kr
Abstract
Recent scientific studies have advanced the notion of chronic inflammation as a major risk factor underlying aging and age-related diseases. In this review, low-grade, unresolved, molecular inflammation is described as an underlying mechanism of aging and age-related diseases, which may serve as a bridge between normal aging and age-related pathological processes. Accumulated data strongly suggest that continuous (chronic) upregulation of pro-inflammatory mediators (e.g., TNF-alpha, IL-1beta, IL-6, COX-2, iNOS) are induced during the aging process due to an age-related redox imbalance that activates many pro-inflammatory signaling pathways, including the NF-kappaB signaling pathway. These pro-inflammatory molecular events are discussed in relation to their role as basic mechanisms underlying aging and age-related diseases. Further, the anti-inflammatory actions of aging-retarding caloric restriction and exercise are reviewed. Thus, the purpose of this review is to describe the molecular roles of age-related physiological functional declines and the accompanying chronic diseases associated with aging. This new view on the role of molecular inflammation as a mechanism of aging and age-related pathogenesis can provide insights into potential interventions that may affect the aging process and reduce age-related diseases, thereby promoting healthy longevity.
PMID: 18692159 [PubMed - indexed for MEDLINE]
// - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - End memo item - - //














